For the better-seeing eyes at baseline , the mean change in composite score with @ mg ranibizumab at the @-month visit was @ more ( @ % confidence interval -LSB- CI -RSB- , @-@ @ ) than sham for RIDE patients and @ more ( @ % CI,-@ @ to @ ) than sham for RISE patients .